WALTHAM, Mass., July 24, 2026 /PRNewswire/ -- Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Biomedical's capabilities in cell line development and strengthens its ability to support biopharmaceutical workflows from early development through manufacturing. NanoCellect® WOLF G2® cell sorting platform introduces gentle, microfluidic-based cell selection and isolation, complementing Nova Biomedical's existing Solentim portfolio for clone generation, verification, and growth analy…READ FULL ARTICLE